Alliqua BioMedical Inc. (ALQA)

2.12
0.01 0.47
NASDAQ : Health Technology
Prev Close 2.11
Open 2.15
Day Low/High 2.12 / 2.16
52 Wk Low/High 1.58 / 4.60
Volume 3.98K
Avg Volume 31.50K
Exchange NASDAQ
Shares Outstanding 5.00M
Market Cap 10.86M
EPS -6.00
Div & Yield N.A. (N.A)

Latest News

Alliqua BioMedical, Inc. Reports Third Quarter Of Fiscal Year 2017 Financial Results And Increases Fiscal Year 2017 Financial Outlook

Alliqua BioMedical, Inc. Reports Third Quarter Of Fiscal Year 2017 Financial Results And Increases Fiscal Year 2017 Financial Outlook

Q3'17 Product revenue from continuing operations increased 14% year-over-year, led by Biologics growth of 70% year-over-year

Alliqua BioMedical, Inc. Announces 1-for-10 Reverse Stock Split

Alliqua BioMedical, Inc. Announces 1-for-10 Reverse Stock Split

Shares of Common Stock Will Begin Trading on Split-Adjusted Basis on October 6, 2017

Alliqua BioMedical, Inc. Reports Second Quarter Of Fiscal Year 2017 Financial Results

Alliqua BioMedical, Inc. Reports Second Quarter Of Fiscal Year 2017 Financial Results

Q2'17 Product revenue from continuing operations increased 34% year-over-year, led by Biologics growth of 106% year-over-year

Alliqua BioMedical, Inc. Reports First Quarter Of Fiscal Year 2017 Financial Results

Q1'17 Product revenue from continuing operations increased 28% year-over-year, led by Biologics growth of 197% year-over-year

Alliqua BioMedical, Inc. Announces Preliminary First Quarter Fiscal 2017 Revenue And Updates Fiscal Year 2017 Outlook; Earnings Conference Call Scheduled For May 9, 2017

Preliminary Q1'17 product sales increase 28% year-over-year led by biologics growth of approximately 200% year-over-year

Alliqua BioMedical, Inc. To Present New Data At The Spring 2017 Symposium On Advanced Wound Care

Features Five New Poster Presentations on Interfyl™ and UltraMIST® Therapy

Alliqua BioMedical, Inc. Reports Fourth Quarter And Fiscal Year 2016 Financial Results

FY'16 Product revenue from continuing operations increased 60% year-over-year, led by Biologics growth in excess of 115% year-over-year

Alliqua BioMedical, Inc. Reports Third Quarter And Nine-Months Fiscal Year 2016 Financial Results

Alliqua BioMedical, Inc. Reports Third Quarter And Nine-Months Fiscal Year 2016 Financial Results

Third Quarter Product Revenue Growth of 18% year-over-year

Alliqua BioMedical, Inc. Announces Expansion Of Medicare Reimbursement Coverage For MIST Therapy®

Alliqua BioMedical, Inc. Announces Expansion Of Medicare Reimbursement Coverage For MIST Therapy®

Medicare Coverage for MIST Therapy® Now Includes All Medicare Administrative Contractors

Alliqua BioMedical, Inc. To Acquire Soluble Systems, LLC

Alliqua BioMedical, Inc. To Acquire Soluble Systems, LLC

Transaction Further Establishes Alliqua BioMedical as a Leading Provider of Regenerative Technologies

Alliqua BioMedical, Inc. Reports Second Quarter And Six Months Fiscal Year 2016 Financial Results

Alliqua BioMedical, Inc. Reports Second Quarter And Six Months Fiscal Year 2016 Financial Results

Revenue Growth from Continuing Operations of 80% year-over-year; Gross Margin Increases to 64%

TheStreet Quant Rating: D- (Sell)